PsiQuantum and National Cancer Center Japan Partner to Accelerate Drug Discovery for Healthcare
Article excerpt
Highlighted: the sentence this signal was extracted from
PsiQuantum and National Cancer Center Japan partner to accelerate drug discovery for healthcare. March 12, 2026 Press play to listen to this content PALO ALTO, Calif., March 12, 2026 - PsiQuantum announced today that the company has signed a collaborative research agreement with the National Cancer Center Japan, a leading cancer treatment and research facility, to advance applications in oncology and healthcare for utility-scale quantum computers. This new agreement underscores the enormous potential for utility-scale quantum computing across the healthcare value chain, specifically in research and development, resource allocation, and patient outcomes in cancer treatment. Under the newly formed collaboration, PsiQuantum will work alongside the National Cancer Center Japan to advance fault-tolerant quantum algorithm development and collaborate with the National Cancer Center Japan and other leading pharmaceutical companies in Japan in the development of clinically relevant quantum applications. The partnership will also utilize PsiQuantum's software suite, Construct - a secure, end-to-end platform for designing, analyzing, and optimizing algorithms for fault-tolerant quantum computing. "PsiQuantum is proud to work alongside the National Cancer Center Japan as we explore what utility-scale quantum computing will be able to deliver in designing new treatments for the...
Keep reading with a free account
The rest of this article, and every signal for PsiQuantum, is in your free account.
